PMID: 15378133Sep 21, 2004Paper

Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs

Journal of Cardiovascular Pharmacology and Therapeutics
Bramah N Singh, Nitin Wadhani

Abstract

In recent years there has been a major reorientation of drug therapy for cardiac arrhythmias, its changing role, and above all, a radical change in the class of arrhythmia drugs because of their impact on mortality. The decline in the use of sodium-channel blockers has led to an ex panding use of beta-blockers and simple or complex class III agents for controlling cardiac arrhythmias. Success with these agents in the context of their side effects has spurred the development of compounds with simpler ion-channel blocking properties that have less complex adverse reactions. The resulting so-called pure class III agents, such as dofetilide or ibutilide, were found to have antifibrillatory effects in atrial fibrillation and flutter and in ventricular tachyarrhythmias. Such agents are effective and have diversity, but they have come into therapeutics with a price: the sometimes-fatal torsades de pointes. The drug amiodarone, a complex compound that was synthesized as an antianginal agent, has been an exception in this regard. Its therapeutic use is associated with a negligibly low incidence of torsades de pointes, even though the drug produces significant bradycardia and QT lengthening to 500 to 700 msec. Recent electrophysiologic s...Continue Reading

References

Aug 10, 1989·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial (CAST) Investigators
Apr 1, 1989·The American Journal of Cardiology·B N Singh
Aug 1, 1970·British Journal of Pharmacology·B N Singh, E M Vaughan Williams
Apr 1, 1968·The American Journal of Cardiology·M B Bacaner
Oct 1, 1983·American Heart Journal·B N Singh
Nov 1, 1994·The American Journal of Cardiology·G CuiB N Singh
Dec 1, 1993·JAMA : the Journal of the American Medical Association·R R MakkarM H Lehmann
Jul 1, 1997·Cardiovascular Research·I KodamaJ Toyama
Dec 12, 1997·Journal of Cardiovascular Electrophysiology·S SicouriC Antzelevitch
Mar 7, 1998·Circulation·K T Murray
Oct 13, 1998·Journal of the American College of Cardiology·E DrouinF Charpentier
Mar 25, 1999·Journal of Cardiovascular Electrophysiology·B N Singh
Nov 24, 1999·The American Journal of Cardiology·B N SinghJ S Sarma
Feb 23, 2000·Journal of Cardiovascular Pharmacology and Therapeutics·B N Singh
Jun 27, 2000·Journal of Cardiovascular Electrophysiology·C NapolitanoS G Priori
Jan 24, 2002·Nature·Stanley Nattel
May 9, 2002·Expert Opinion on Investigational Drugs·William C Stanley
Nov 8, 2002·American Heart Journal·Mark E AndersonUNKNOWN Duke Clinical Research Institute/American Heart Journal Expert Meeting on Repolarization Changes
Mar 5, 2004·The New England Journal of Medicine·Dan M Roden
Sep 21, 2004·Journal of Cardiovascular Pharmacology and Therapeutics·William C Stanley

❮ Previous
Next ❯

Citations

Jun 19, 2009·Cardiovascular Drugs and Therapy·Reinis VilskerstsMaija Dambrova
Sep 7, 2007·The New England Journal of Medicine·Bramah N SinghUNKNOWN EURIDIS and ADONIS Investigators
Nov 17, 2007·Cardiovascular Research·Lin WuLuiz Belardinelli
Jun 23, 2011·Toxicological Sciences : an Official Journal of the Society of Toxicology·Liang GuoKyle L Kolaja
Apr 12, 2014·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Ansgar BergAsle Hirth
Dec 23, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Hui LiuGui-Rong Li
Mar 23, 2011·Pharmacology & Therapeutics·Jérôme ThireauSylvain Richard
Nov 13, 2008·Current Problems in Cardiology·Michael D Faulx, Gary S Francis
Nov 29, 2007·Pharmacotherapy·Paul P Dobesh, Toby C Trujillo
Feb 13, 2013·Cardiovascular Therapeutics·Enrico VizzardiAntonio Curnis
May 23, 2006·Progress in Cardiovascular Diseases·Spyros KokolisJohn Kassotis
Jul 5, 2005·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Rashmi R Shah, Luc M Hondeghem
Mar 18, 2010·Acta Physiologica Hungarica·Ioana MozosA Cristescu
Jun 1, 2014·Journal of Molecular and Cellular Cardiology·Chunyun DuJules C Hancox
Mar 29, 2008·Journal of Intensive Care Medicine·Stephanie Mallow Corbett, Jill A Rebuck
Oct 8, 2005·Journal of Cardiovascular Pharmacology and Therapeutics·Bipinpreet S NagraBharat K Kantharia
Sep 21, 2004·Journal of Cardiovascular Pharmacology and Therapeutics·Bernard R Chaitman
Mar 6, 2010·Circulation Research·Hee Cheol Cho, Eduardo Marbán
Sep 8, 2006·Current Cardiology Reports·Bramah N Singh
Jan 31, 2019·European Cardiology·Giacinta GuariniMario Marzilli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.